Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, HC Wainwright Analyst Says

Halozyme Therapeutics (NASDAQ:HALO) had its price objective raised by HC Wainwright from $95.00 to $115.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 34.10% from the stock’s previous close.

Several other equities analysts have also weighed in on HALO. Morgan Stanley cut their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 31st. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. UBS Group reiterated a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Finally, Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $83.60.

Halozyme Therapeutics Price Performance

HALO opened at $85.76 on Friday. The stock has a fifty day moving average price of $75.74 and a 200 day moving average price of $71.25. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics has a 1 year low of $61.22 and a 1 year high of $86.00. The stock has a market cap of $10.17 billion, a price-to-earnings ratio of 30.85, a PEG ratio of 0.35 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business’s revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts forecast that Halozyme Therapeutics will post 7.54 EPS for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares in the company, valued at $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total value of $124,653.75. Following the completion of the sale, the director directly owned 42,044 shares in the company, valued at approximately $3,225,195.24. This represents a 3.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 72,477 shares of company stock valued at $5,102,643. Company insiders own 2.50% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HALO. Norges Bank acquired a new position in Halozyme Therapeutics in the 4th quarter valued at approximately $128,201,000. William Blair Investment Management LLC acquired a new position in shares of Halozyme Therapeutics in the fourth quarter valued at $124,031,000. Voloridge Investment Management LLC bought a new position in Halozyme Therapeutics in the third quarter worth $77,587,000. Qube Research & Technologies Ltd bought a new position in Halozyme Therapeutics in the second quarter worth $51,295,000. Finally, Assenagon Asset Management S.A. boosted its stake in Halozyme Therapeutics by 4,578.9% during the second quarter. Assenagon Asset Management S.A. now owns 997,643 shares of the biopharmaceutical company’s stock worth $78,086,000 after buying an additional 976,321 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Record quarterly results exceeded expectations. Second-quarter revenue rose 48% year over year to $481 million, beating estimates of approximately $402 million. Adjusted earnings reached $2.28 per diluted share, above consensus estimates ranging from $1.79 to $1.82 and up from $1.54 a year earlier. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Royalty growth remained a key catalyst. Royalty revenue increased 50% year over year to $308 million, highlighting continued commercial adoption of Halozyme’s drug-delivery technologies and the scalability of its royalty-based business. Halozyme Q2 Key Metrics
• Positive Sentiment: Management raised 2026 guidance. Halozyme now expects total revenue of $1.835 billion to $1.910 billion, royalty revenue of $1.220 billion to $1.245 billion, adjusted EBITDA of $1.225 billion to $1.280 billion, and non-GAAP EPS of $8.65 to $9.00. The EPS outlook is well above the roughly $8.02 analyst consensus. Halozyme Q2 2026 Results Presentation
• Positive Sentiment: Business development exceeded targets. The company signed five new ENHANZE and Hypercon collaboration agreements during 2026, already surpassing its goal of three agreements for the full year. This could strengthen Halozyme’s longer-term pipeline and royalty growth prospects. Halozyme Q2 2026 Earnings Call Transcript

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.